Insider · CIK 0001692747
Jason A. Leverone
Files at OKUR (OnKure Therapeutics, Inc.). First filing Apr 8, 2025, latest Sep 23, 2026.
Jason A. Leverone files SEC Form 4 as CFO at OKUR (OnKure Therapeutics, Inc.). Since Apr 8, 2025, Jason A. Leverone has reported 0 open-market buys worth $0 and 6 open-market sells worth $14k, the latest filed on Sep 23, 2026.
A track record needs three past buys with six months of prices behind them; Jason A. Leverone has 0, so none is measured yet.
The newest scored trade: sold $898 of OKUR on Sep 21, 2026, filed Sep 23, 2026, scored 30 (weak). In the last 12 months: 0 buys worth $0 and 3 sells worth $3,046.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
OKUR: OnKure Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | OnKure Therapeutics, Inc. | $898 302 shares | -2% | - | |
| 30Weak | OnKure Therapeutics, Inc. | $1,251 301 shares | -2% | +117% from low-20% from high | |
| 30Weak | OnKure Therapeutics, Inc. | $896 302 shares | -2% | +62% from low-67% from high | |
| 30Weak | OnKure Therapeutics, Inc. | $795 303 shares | -2% | +43% from low-86% from high | |
| 30Weak | OnKure Therapeutics, Inc. | $722 303 shares | -2% | +32% from low-87% from high | |
| 35Weak | OnKure Therapeutics, Inc. | $9,178 3,122 shares | -19% | 0% from low-84% from high |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 21, 2026 | OKUR OnKure Therapeutics, Inc. | SOpen-market sale Class A Common Stock | -302 | $2.97 | $898 | 18,500 | 20 d ago |
| Mar 23, 2026 | OKUR OnKure Therapeutics, Inc. | SOpen-market sale Class A Common Stock | -301 | $4.16 | $1,251 | 16,000 | Mar 24, 2026 |
| Dec 22, 2025 | OKUR OnKure Therapeutics, Inc. | SOpen-market sale Class A Common Stock | -302 | $2.97 | $896 | 16,301 | Dec 23, 2025 |
| Sep 22, 2025 | OKUR OnKure Therapeutics, Inc. | SOpen-market sale Class A Common Stock | -303 | $2.62 | $795 | 12,603 | Sep 24, 2025 |
| Jun 23, 2025 | OKUR OnKure Therapeutics, Inc. | SOpen-market sale Class A Common Stock | -303 | $2.38 | $722 | 12,906 | Jun 25, 2025 |
| Apr 4, 2025 | OKUR OnKure Therapeutics, Inc. | SOpen-market sale Class A Common Stock | -1,278 | $3.33 | $4,253 | 15,053 | Apr 8, 2025 |
| Apr 7, 2025 | OKUR OnKure Therapeutics, Inc. | SOpen-market sale Class A Common Stock | -1,844 | $2.67 | $4,925 | 13,209 | Apr 8, 2025 |
Questions about Jason A. Leverone
Answered from the filings on this page, as of the latest one.
Is Jason A. Leverone buying or selling?
In the last 12 months Jason A. Leverone reported 0 open-market buys worth $0 and 3 open-market sells worth $3,046 on SEC Form 4; the latest was sold $898 of OKUR on Sep 21, 2026. Grants, option exercises and tax withholding are not counted.
How did Jason A. Leverone's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jason A. Leverone has 0.
Where does Jason A. Leverone file Form 4?
Jason A. Leverone has filed Form 4 at OKUR (OnKure Therapeutics, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.